Prelude Therapeutics (PRLD)
NASDAQ: PRLD
· Real-Time Price · USD
0.84
-0.10 (-11.11%)
At close: Aug 15, 2025, 3:59 PM
0.87
4.05%
After-hours: Aug 15, 2025, 04:54 PM EDT
Prelude Therapeutics Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -32.09M | -28.73M | -32.27M | -34.74M | -31.43M | -33.08M | -30.61M | -30.43M | -27.72M | -28.64M | -29.96M | -27.37M | -29.46M | -32.84M | -30.69M | -26.86M | -21.3M |
Depreciation & Amortization | 435K | 489K | -3.28M | 452K | 426K | 331K | 279K | 281K | 278K | 362K | 337K | 318K | 307K | 290K | 266K | 199K | 160K |
Stock-Based Compensation | 3.83M | 3.77M | 12.02M | 6.1K | 5.55M | 5.91M | 6.71M | 6.73M | 6.26M | 5.84M | 6.44M | 6.03M | 6.83M | 5.78M | 7.03M | 4.24M | 3.89M |
Other Working Capital | -4.97M | 2.48M | -649K | 4.99M | -5.84M | 4.18M | -454K | -2.63M | -9.31M | 2.49M | -2.42M | 1.93M | -727K | 3.6M | -3.6M | 501K | -772K |
Other Non-Cash Items | 463K | -563K | -2.9M | 4.99M | 4.64M | 608K | 454K | 442K | -14K | 258K | 1.43M | 1.47M | 1.16M | 400K | 356K | 290K | 282K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | -1.07M | -1.6M | -359K | n/a | n/a | n/a | n/a | n/a | 1.01M | 356K | n/a | n/a |
Change in Working Capital | -6.88M | 4.29M | -862K | 6.07M | -5.21M | 3.72M | -926K | -4.33M | -8.94M | -751K | 1.31M | 1.09M | -725K | -333K | 902K | 2.23M | 829K |
Operating Cash Flow | -34.23M | -20.74M | -27.3M | -23.06M | -31.79M | -23.58M | -25.68M | -27.67M | -30.13M | -22.93M | -20.44M | -18.47M | -21.89M | -25.7M | -21.77M | -19.91M | -16.14M |
Capital Expenditures | -47K | -53K | -63K | -359K | -289K | -1.13M | -591K | -983K | -810K | -393K | -916K | -758K | -952K | -297K | -659K | -381K | -986K |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | -8.87K | -15.64K | 74.44K | -18.81K | -1.75K | -22.52K | -17.94K | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | -9.46M | -7.33M | -31.99M | -7.88M | -5.49M | -59.38M | -34.11M | -120.94M | -7.19M | -33.25M | -58.83M | -27.14M | n/a | -1.51M | -259.97M | n/a | n/a |
Sales Maturities Of Investments | 71.7M | 29.5M | 42.79M | 34.36M | 37M | 68.25M | 49.75M | 46.5M | 26M | 35M | 81.36M | 45.08M | 42.5M | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | 26.48K | 31.51K | 8.87K | 15.64K | -74.44K | 18.81K | 1.75K | 22.52K | 17.94K | 42.5K | -1.51K | -259.97M | n/a | n/a |
Investing Cash Flow | 62.19M | 22.12M | 10.73M | 26.12M | 31.22M | 7.74M | 15.04M | -75.43M | 18M | 1.35M | 21.61M | 17.18M | 41.55M | -1.8M | -260.63M | -381K | -986K |
Debt Repayment | -155K | -151K | -148K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | 34.00 | -18 | -16 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | -5K | 117K | 17K | 59K | -14K | 301K | -16K | 111.34M | -269K | 155K | 148K | 359K | 153K | 1.95M | 711K | 422K | 386K |
Financial Cash Flow | -160K | -34K | -131K | 59K | -14K | 25.24M | 88K | 111.34M | -269K | 155K | 148K | 359K | 153K | 1.95M | 711K | 422K | 161.81M |
Net Cash Flow | 27.8M | 1.34M | -16.69M | 3.12M | -584K | 9.39M | -10.55M | 8.24M | -12.4M | -21.42M | 1.32M | -928K | 19.81M | -25.55M | -281.69M | -19.87M | 144.68M |
Free Cash Flow | -34.28M | -20.8M | -27.36M | -23.42M | -32.08M | -24.71M | -26.27M | -28.65M | -30.94M | -23.32M | -21.36M | -19.23M | -22.85M | -26M | -22.43M | -20.29M | -17.13M |